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Abstract
Up till now, research on inflammatory bowel disease [IBD] has mainly been focused on the immune 
cells present in the gastrointestinal tract. However, recent insights indicate that stromal cells also 
play an important and significant role in IBD pathogenesis. Stromal cells in the intestines regulate 
both intestinal epithelial and immune cell homeostasis. Different subsets of stromal cells have 
been found to play a role in other inflammatory diseases [e.g. rheumatoid arthritis], and these 
various stromal subsets now appear to carry out also specific functions in the inflamed gut in 
IBD. Novel potential therapies for IBD utilize, as well as target, these pathogenic stromal cells. 
Injection of mesenchymal stromal cells [MSCs] into fistula tracts of Crohn’s disease patients is 
already approved and used in clinical settings. In this review we discuss the current knowledge 
of the role of stromal cells in IBD pathogenesis. We further outline recent attempts to modify the 
stromal compartment in IBD with agents that target or replace the pathogenic stroma.
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1. Introduction
Inflammatory bowel disease [IBD] incidence is still increasing 
worldwide, mostly due to an accelerating incidence in newly in-
dustrialized countries.1 Although clear progress has been made, the 
exact pathogenesis of IBD is still poorly understood. The current 
working model of IBD pathogenesis proposes a dysfunctional epi-
thelial barrier that finally leads to an aberrant immune response to 
the intestinal bacteria. Recent research demonstrates that, in add-
ition to intestinal epithelial and inflammatory cells, stromal cells 
play an important role in IBD pathogenesis. So far, therapies for 
IBD have been mainly focused on the targeting of immune cells, and 
this has given rise to the development and therapeutic application 
of a number of biologic therapies, small molecules (like janus kin-
ases inhibitors), and other immunomodulators. Biologic therapies 
such as anti-TNF-α and anti-IL-23/12 therapies have been suc-
cessfully introduced into the clinic. However, attempts to block a 
number of additional cytokine networks, like for example blockage 
of interferon-γ 2 [IFN-γ] or IL-17A,3 were rather disappointing. 
With immune-modulating therapies, mucosal healing in Crohn’s 
disease [CD] is only achieved in ≤45% of patients.4,5 Subsequently, 
the risk of surgery within 10 years after diagnosis is still 46.6% and 
15.6% for, respectively, CD and ulcerative colitis [UC].6 In add-
ition, a definite curative treatment for IBD patients has not yet been 
discovered. It might be important to develop alternative therapies 
that target pathogenic stromal cells in IBD, which could probably 
intervene earlier in the inflammatory cascade and thereby have a 
better chance of delaying disease progression.
This review will focus on the role that stromal cells, in particular 
fibroblasts, play in the pathogenesis of IBD, thereby focusing on 
their role in the inflamed, non-fibrotic intestinal tissue. First, we will 
describe the current knowledge regarding the function of stromal 
cells in the healthy intestine. Thereafter, we will discuss the role of 
activated stromal cells in diseased tissue and highlight the findings 
in the current literature on stromal cells in IBD, focusing on their 















































































recently discovered opportunities for developing potential therapies 
pertaining to targeting stromal cells and replacement of stromal cells, 
via mesenchymal stromal cell [MSC] therapy, will be highlighted.
1.1. Definitions
There seems to be a lack of consensus pertaining to the no-
menclature of stromal cells in general. Terms such as ‘stromal 
cell’, ‘mesenchymal cell’, ‘fibroblast’, and ‘fibroblast-like 
cell’ are used seemingly interchangeably within and between 
studies. In this review, we will refer to ‘stromal cells’ as non-
hematopoietic, non-epithelial, and non-endothelial cells.7 In 
general, the most abundant stromal cells are fibroblasts, fol-
lowed by myofibroblasts, smooth muscle cells, pericytes, and 
mesenchymal stromal cells. In the human intestine, stromal cells 
can be detected in all layers of the gut wall, from the mucosa 
to the serosa. Mostly, stromal cells are defined as being nega-
tive for cell surface markers, such as cluster of differentiation 
[CD]31 [endothelial cells], CD45 [immune cells], keratins, or 
epithelial cell adhesion molecule [EpCAM; epithelial cells],8–10 
while they are positive for the cytoskeletal marker vimentin. 
Fibroblasts, more specifically, are mostly reported to be posi-
tive for collagen [COL] types I  and -III, CD90, and fibroblast 
activation protein [FAP].11–13 However, as we will discuss later 
in detail, subsets of fibroblasts have been identified that are 
negative for FAP and CD90, indicating that fibroblasts also 
form a heterogenous group of cells. Furthermore, fibroblasts 
are recognizable, through their distinct morphology in vitro, 
as spindle-shaped cells with a flat nucleus and slender cyto-
plasmic processes.8 However their morphological properties are 
more difficult to detect in tissues. MSCs, known for their thera-
peutic capacity after culture, are defined as CD105-, CD73-, 
and CD90-positive cells that are able to differentiate [in vitro] 
into osteoblasts, chondrocytes, and adipocytes.14 For pericryptic 
myofibroblasts, which show properties of both fibroblasts and 
smooth muscle cells,15 there is consensus in the nomenclature, 
since these cells are defined as cells that are vimentin- and alpha 
smooth muscle actin [α-SMA]–positive, but do not express the 
smooth muscle cell marker desmin.12
2. Stromal Cells in Intestinal Homeostasis
Most stromal cells in the gut wall derive from the serosal mesothe-
lium, which originates from the mesoderm, during embryonic de-
velopment.16,17 Furthermore, stromal cells in the inflamed gut may 
also develop from other cell types through the process of epithelial-
to-mesenchymal transition [EMT] or endothelial-to-mesenchymal 
transition [EndoMT].18–21 Finally, stromal cells, and especially MSCs 
and circulating fibrocytes, are able to migrate from the bone marrow 
towards the intestines.22
2.1. The gut stroma
The gut stroma provides structure and form, and primarily con-
sists of stromal cells and extracellular matrix [ECM]. Within the 
stroma, fibroblasts are mainly known for their role in the pro-
duction of the ECM by secreting types I, II, and V collagens, and 
fibronectin, and matrix remodelling through proteolytic enzymes, 
including matrix metallopreinases [MMPs].23 A well-known com-
plication of excessive ECM production by fibroblasts in IBD is 
fibrosis. In this review, we will not focus on fibrosis, since excel-
lent reviews have already been published on the role of fibroblasts 
in fibrosis.24–26 It is, however, an oversimplification to see fibro-
blasts only as passive matrix-depositing cells, thereby providing 
epithelial support and tissue structure. Recent literature shows 
that fibroblasts also play an important role in maintaining tissue 
homeostasis by their interaction with both epithelial and immune 
cells.
2.2. Epithelial cell homeostasis
The intestine is covered by a monolayer of epithelial cells. These 
cells are generated from stem cells in the base of intestinal crypts 
and then migrate along the crypt lining, while they differentiate into 
specialized epithelial cells like absorptive enterocytes, goblet cells, 
enteroendocrine cells, tuft cells, M cells, and Paneth cells.27 They 
have a rapid turnover, and eventually the mature epithelial cells are 
shed at the top of the crypt into the lumen, renewing the crypt every 
4–5 days.28 Epithelial cell homeostasis is important because epithe-
lial cells form the first line of defence against pathogens, and they are 
also responsible for the absorption of nutrients.
Myofibroblasts are described as the stromal cells that are im-
portant for maintaining epithelial homeostasis. In the human in-
testine, myofibroblasts are found along the crypts, and they also 
surround the intestinal stem cell niche  is comprised of Lgr5+ stem 
cells and Paneth cells.29 These myofibroblasts have an important 
role in the process of intestinal epithelial cell renewal via paracrine 
interactions.30 Various pathways, such as the Wnt and bone morpho-
genetic protein [BMP] pathways, are able to modulate stem cell func-
tion and differentiation in these intestinal niches.11 Wnt signaling 
is necessary for maintaining non-differentiated proliferating Lgr5+ 
stem cells, while BMP signaling antagonizes Wnt signaling signa-
ture genes and induces differentiation of epithelial cells.31–34 Multiple 
studies have shown that myofibroblasts play an important role in 
both of these pathways by secreting, for example, Wnt ligands and 
BMP antagonists.11,35,36 Myofibroblasts, specifically in the basal part 
of the colon crypt, express the BMP antagonists gremlin and noggin, 
suggesting that they inhibit BMP signaling in the basal crypt regions, 
yet allow BMP signaling to take place in the upper crypt regions.36 
This differential expression of BMP signaling in specific places in 
the intestinal crypt suggests heterogeneity within the myofibroblast 
population. Degirmenci and colleagues identified Gli1pos fibroblasts 
with a close relation to the bases of intestinal crypts in mice to be 
important for epithelial integrity by production of Wnt and thereby 
stem cell renewal.37 Another study further subdivided the Gli1pos cells 
into CD90-positive and -negative fibroblasts.38 Those authors found 
that CD90pos fibroblasts, in contrast to CD90neg fibroblasts, produce 
BMP antagonists and Wnt ligands, like gremlin and Wnt2b, and sup-
port organoid growth.38 Interestingly, the CD90pos fibroblasts could 
be further divided in an α-SMA–positive and –negative population. 
Since myofibroblasts are defined as being α-SMA–positive cells, this 
suggests that fibroblasts also play a role in epithelial homeostasis 
and barrier function, which is often disturbed in IBD.37 Moreover, in 
human samples it was also found that a specific fibroblast popula-
tion contributes to the maintenance of the epithelial homeostasis.39 
This population, identified by CD142 expression, was found close to 
the epithelial monolayer, and single-cell RNA-sequencing [scRNA-
seq] revealed the expression of different BMP and Wnt ligands. 
Overall, evidence of the specific physical location of these intestinal 
[myo]fibroblasts, close to the epithelial layer, and their expression of 
relevant markers, shows that they are able to regulate the function 
and fate of epithelial progenitors and thereby intestinal epithelial 
homeostasis.















































































2.3. Immune cell homeostasis
Besides epithelial cell homeostasis, stromal cells also influence in-
testinal immune cell homeostasis in the intestine. This is the pro-
cess in which immune cell responses are in a steady-state condition, 
because pathogens are recognized and cleared at an early stage 
without immunogenic responses towards non-pathogenic peptides. 
The intestinal mucosal immune system consists of a variety of im-
mune cells that reside in the healthy gut, either organized in Peyer’s 
patches, in lymph nodes, or scattered in the various layers of the gut. 
Upon encountering foreign proteins, antigen-presenting cells, such 
as dendritic cells, present the peptides to lymphocytes in the organ-
ized immune structures in the gut, which activates and attracts other 
lymphocytes to the gut.40
Stromal cells influence immune cell homeostasis via direct 
cell–cell contact with immune cells or through the production of 
chemokines and cytokines.41 Intestinal fibroblasts are able to pro-
duce, for example, interleukin [IL]-6, IL-8, chemokine ligand 2 
[CCL2/MCP-1],41–44 and chemokine ligand 5 [CCL5/RANTES].45 
CCL2 binds to chemokine receptor 2 [CCR2], mainly expressed by 
monocytes, whereas CCL5 binds to several receptors, mainly ex-
pressed by T cells, and thereby fibroblasts facilitate the recruitment 
of both myeloid cells and lymphocytes to the site of inflammation. 
Myofibroblasts and fibroblasts are also able to affect mucosal T cells 
via direct cell–cell contact. In non-diseased human colonic lamina 
propria, these stromal cells express programmed death-ligand 1 
[PD-L1] and PD-L246, which are immune checkpoints that bind 
PD1 on T cells during antigen presentation.47 Fibroblasts are able 
to suppress the proliferation of CD4pos T cells via PD-L1 and PD-L2 
and thereby prevent autoimmunity.46 Colonic fibroblasts can also 
indirectly affect T cells by induction of retinoic acid production in 
dendritic cells,48 which is able to block T helper [Th]1 and Th17 dif-
ferentiation and to enhance regulatory T cell [Treg] differentiation. 
Furthermore, fibroblasts have been described as being part of the 
innate immune system because of their ability to recognize pathogen 
invasion or cell damage.13,49,50 They can detect pathogen-associated 
molecular patterns [PAMPs] and damage-associated molecular pat-
terns [DAMPs] through toll-like receptors [TLRs], which triggers 
the release of chemokines.51 Indeed, CD90pos fibroblasts are known 
to express various TLRs.50 By the expression of MHC class II mol-
ecules, colonic myofibroblasts are, upon activation, also able to act 
as non-professional antigen-presenting cells.13,52 Through both MHC 
class-II expression and the production of prostaglandin E2, human 
colonic [myo]fibroblasts from non-diseased mucosa have been re-
ported as contributing to the maintenance of colonic immunological 
tolerance by promoting the expansion of regulatory FOXP3pos T cells 
[Tregs].53 Together, these observations show that intestinal stromal 
cells are able to modify the mucosal immune landscape via different 
pathways. However, some caution and careful interpretation of the 
data is needed, since most of these studies used allogeneic immune 
cells and in vitro–cultured stromal cells, which could have gained 
their activated immunoregulatory phenotype through culturing.
3. Stromal Cells in Diseased Tissue
Upon organ damage, resident stromal cells become activated. In in-
flammatory diseases, especially in rheumatoid arthritis [RA], there 
has been more focus on the role of stromal cells in the last decade. 
In this review, we will use current literature in RA on stromal cells 
to understand more about the role and function that stromal cells 
might have in other inflammatory conditions and thereby IBD. RA, 
characterized by painful swellings of joints that will eventually lead 
to bone erosion and joint deformation,54 shows immunological simi-
larities with IBD and many immunomodulating therapies currently 
used in IBD were initially explored and approved in RA. In the in-
flamed joints, leukocytes and a variety of innate effector cells ac-
cumulate in the synovium, which is similar to what occurs in the 
bowel of IBD patients, together with expansion of the already pre-
sent lining of fibroblast-like synoviocytes [FLSs].55 Hyperplasia of 
this specific type of fibroblast, found in the synovium, is one of the 
hallmarks of RA, and therefore several studies have been performed 
to identify and characterize the potential pathogenicity of FLSs in 
RA. Both the activation of the immune system and disrupted matrix 
production by the hyperplastic FLSs contribute to cartilage damage 
and bone erosion.56 In addition to RA, we will also shortly touch on 
stromal subsets identified in cancer.
3.1. Stromal cell subsets in RA
In RA, several attempts have been undertaken to identify different 
subtypes of FLSs in the inflamed joint. scRNA-seq of RA synovial 
knee tissue revealed the presence of at least two main fibroblasts 
clusters.57 CD55pos fibroblasts, defining subset 1, were mainly found 
in the synovial lining and showed expression of hyaluronan synthase 
1, which is important for the production of synovial fluid.57 On 
the other hand, CD90pos fibroblasts, defining subset 2, were found 
in the synovial sub-lining of the joint and showed high expression 
of C-X-C motif chemokine 12 [CXCL12]. In accordance, another 
group showed that, within the FAPα pos fibroblasts population in the 
mouse synovium, CD90-positive and -negative fibroblasts were also 
found to have different functions and location.58 Interestingly, the 
severity of the joint inflammation correlated with the number of 
FAPα posCD90pos cells and not with the number of FAPα posCD90neg 
cells. In the murine intestine, similar to the situation described above, 
these CD90pos fibroblasts were also identified, and found to be spe-
cifically located at the base of the crypt,38 which could indicate that 
CD90pos fibroblasts have an organ-specific cellular location. Another 
recent study in RA identified three major stromal subsets defined by 
CD90 and CD34 expression.59 One of these subsets, CD34negCD90pos 
cells, was a specific expanded FLS subset in RA-affected synovium. 
This population of FLSs showed involvement in bone destruction 
in RA by high tumor necrosis factor ligand superfamily member 11 
[TNFSF11] expression levels; TNFSF11 is a key factor for osteoclast 
differentiation and activation. In contrast, CD34negCD90neg fibro-
blasts were less abundant in RA-affected tissue, and especially in 
swollen RA joints. Most of the fibroblasts detected in RA-affected 
joints also showed podoplanin [PDPN] expression.59,60 Although 
PDPN was first identified as a lymphatic vessel marker, cancer-
associated fibroblasts [CAFs] were also found to express PDPN. 
PDPN expression on CAFs was associated with enhanced tumor 
progression61 and inhibition of T cell proliferation.62
3.2. Stromal cell subsets in cancer
Given the immunosuppressive environment in tumors, cancer can 
be seen as the counterpart of IBD, which is defined by an overactive 
immune response. The role of CAFs in cancer has already been dis-
cussed in various excellent recent reviews.63–65 In the present review, 
we will only highlight the most important findings, which have 
relevance for the role of stromal cells in IBD. CAFs have been as-
sociated with increased cancer cell proliferation, cell invasion, and 
the formation of distant metastasis.63,66 Transforming growth factor 
[TGF]-β1 is one of the most abundant cytokines produced by CAFs. 
It was shown that high TGF-β1 levels, which are associated with a 
poor prognosis,67 are an immunosuppressive mechanism of CAFs, 















































































promoting T cell exclusion and the blocking of the T helper 1 [Th1]-
effector phenotype acquisition.68–71 Interestingly, dual treatment 
with anti-TGF-β and anti-PD-L1 in a murine breast cancer model 
changed peritumoral stromal fibroblasts and increased cytotoxic T 
cell counts in the tumor, leading to a significant reduction in tumor 
burden only in mice treated with both antibodies.72 This would indi-
cate that most CAFs are tumor promoting, and that targeting them 
inhibits tumor progression. However, targeting all α-SMApos CAFs 
in mice with pancreatic cancer increased the number of Tregs in 
the tumors and led to more aggressive tumors and decreased sur-
vival.73 This indicates that different subpopulations exist, with dis-
tinct roles in tumor progression. In colorectal cancer, scRNA-seq 
profiling of the tumor and matched non-tumor samples revealed the 
presence of three clusters of fibroblasts, of which two were defined 
as CAFs.74 CAF-A, which was the only CAF population showing 
FAP expression, showed high expression of MMP2 and COL1A2. 
In contrast, CAF-B had a more myofibroblast-like phenotype, with 
high expression of α-SMA. Two different CAF types were also 
found in pancreatic cancer tissue by using FAP and α-SMA staining, 
and defined as inflammatory [i]CAFs and myofibroblastic [my]
CAFs.75 iCAFs were described as activated stellate cells, forming the 
dense tumor stroma and being the main source of IL-6 and IL-11, 
whereas myCAFs were defined by high α-SMA expression and their 
periglandular location. Besides α-SMA, many other markers have 
been proposed as distinguishing certain subtypes of fibroblasts. 
CD14676 or CD29,77 among others, have been associated with breast 
cancer CAF subpopulations. Periostin [POSTN], myosin [MYH]-
11, and PDPN78 have been associated with pancreatic cancer CAF 
subpopulations. These non-overlapping markers show that, at least 
up till now, robust markers identifying specific CAF subsets have not 
been established. The CAF subpopulations exert different functions, 
both on cancer and immune cells. Two studies demonstrated the ef-
fect of a CAF subpopulation, defined by expression of CD10/GPR77 
or fibroblast growth factor 5 [FGF5], respectively, on the promotion 
of cancer stem cells.79,80 Givel et al.,81 on the other hand, observed 
that in ovarian cancers that are enriched for the α-SMA–expressing 
CAF-S1 subset, there is increased accumulation of Tregs. These CAFs 
were able to recruit, retain, and increase survival of CD4posCD25pos 
T cells and then promote differentiation of these T cells into Tregs. 
CXCL12β was highly expressed in this CAF subset compared with 
other CAF subsets, and knockdown of CXCL12 in CAF-S1 reduces 
CD4posCD25pos recruitment in vitro. In summary, it seems plausible, 
that as in the healthy colon, in cancer there are different types of 
stromal cells that have distinct effects on tumor cell growth and/or 
immune cell homeostasis.
4. Stromal Cell Subsets in IBD
Although stromal cell research in IBD is in its infancy, various mech-
anisms have been discovered through which stromal cells affect 
wound healing and modulate the immune milieu in the inflamed in-
testine. Three major contributions towards understanding the role of 
stromal cells in IBD were the recent studies from Kinchen,39Smillie,82 
and Martin,83 in which the stromal cell subsets in the colon of IBD 
patients were analysed using scRNA-seq39,82,83 and mass cytometry 
time-of-flight [CyTOF].39,83 In the study from Kinchen and col-
leagues, 12 different non-epithelial and non-immune cell clusters 
could be detected in the colon of patients with UC. In addition to the 
myofibroblasts, four different clusters of fibroblast-like cells could be 
defined [S1-4]. Cluster S1 was characterized by the expression of non-
fibrillar collagens and elastic fibres, whereas cluster S2 showed high 
CD142 expression, cluster S3 showed high CD55 and COX-2 expres-
sion, and cluster S4, which was barely detectable in the healthy gut, 
yet expanded in UC, showed PDPN and IL-33 upregulation. Smillie 
and colleagues found eight fibroblast clusters in UC tissue, which also 
included one myofibroblast population. The clusters mainly differed 
by expression of Wnt and BMP signaling genes, suggesting their dif-
ferent positions along the intestinal crypt. They also identified one 
fibroblast population, termed inflammation-associated fibroblasts, 
that was expanded in inflamed tissue of UC patients and showed 
enrichment for genes like IL-11, FAP, and IL-13RA2. In contrast, 
Martin and colleagues analysed lamina propria cells from ileal tissue 
from CD patients and identified four stromal clusters; pericytes, 
smooth muscle cells, fibroblasts, and activated fibroblasts.83 The 
two fibroblast subtypes were characterized by expression of platelet-
derived growth factor receptors and genes encoding for ECM pro-
teins. Interestingly, activated fibroblasts strongly expressed CD90 and 
also PDPN. The different functions assigned to the various stromal 
clusters are discussed below, and the most important changes in 
stromal cells in IBD are summarized in Figure 1.
4.1. Wound healing by IBD stromal cells
In order to restore the damaged epithelium in IBD, the migration 
of fibroblasts, collagen deposition, and controlled rebuilding of the 
epithelial layer is essential.84 Already some years ago, it was found 
that the migratory capacity of human colonic lamina propria fibro-
blasts is altered in IBD. In vitro studies showed reduced migratory 
capacity of fibroblasts from IBD patients compared with control 
intestinal fibroblasts.85 This is even further decreased in fibroblasts 
derived from CD fistula patients.86 Furthermore, fibroblasts derived 
from CD or UC inflamed intestines proliferated faster and produced 
an increased amount of collagen in vitro compared with fibroblasts 
from healthy individuals.87 This might explain the increased risk of 
fibrosis in IBD patients, although proliferation and collagen produc-
tion is also needed for epithelial layer repair. Regarding the role of 
stromal cells in restoring the epithelial cell layer, it was shown that 
the CD142pos fibroblast-like subpopulation S2, which is located next 
to the epithelial monolayer and characterized by the expression of 
sheet collagens and different Wnt and BMP ligands, was diminished 
in the colon of UC patients.39 Previously, it has been shown that 
in CD inflamed small intestines the fibroblastic sheath surrounding 
the crypt contained less SMApos and Tenascin-Cpos cells in com-
parison with controls.88 These observations suggest dysregulation 
in the fibroblasts surrounding the crypts in both forms of IBD. In 
addition, after induction of dextran sodium sulfate [DSS] colitis in 
mice, increased numbers of Gli1pos mesenchymal cells, the previously 
mentioned Wnt-secreting subtype of stromal cells surrounding the 
crypts, were found, suggesting their contribution to restoration of 
epithelial homeostasis.37 Together, these studies show the mutual 
interaction between epithelial and stromal cells in wound-healing 
responses in the inflamed intestine.
4.2. IBD stromal cell responses to microbiota
When the epithelial barrier is not intact, intestinal fibroblasts are able 
to directly respond to microbial stimuli, like lipopolysaccharides or 
lipoteichoic acid through expression of TLRs. Activation of TLRs in-
creases, among other cytokines, production of IL-8, IL-6, and IL-1β by 
intestinal fibroblasts.89,90 Besides TLRs, the expression of nucleotide-
binding oligomerization domain–containing protein 2 [NOD2] on 
fibroblasts renders them able to recognize bacterial products, in par-
ticular peptidoglycan-derived molecules containing muramyl dipep-
tide that are produced by both Gram-negative and Gram-positive 















































































bacteria.91 Loss-of-function mutations in NOD2 were one of the 
first risk factors identified for ileal CD.92,93 More recently, Kim and 
colleagues indicated colonic stromal cells as important producers of 
CCL2 in response to C. rodentium infection by activation of NOD244. 
CCL2 is in turn responsible for the recruitment of monocytes. 
Whether NOD2 signaling in IBD stromal cells is altered in response 
to bacteria is not elucidated as yet. On the other hand, intestinal fibro-
blasts upregulate IL-17– and IFN-γ–induced cytokines, like IL-6, 
CXCL1, and CXCL9, upon stimulation with cell-free supernatants 
of microbiota-reactive memory T cells [CD4 posCFSElowICOShigh] from 
IBD patients in vitro.94 These studies show both the direct and indirect 
impact of the intestinal microbiota on stromal cells.
4.3. Immunoregulation by IBD stromal cells
Alongside the effects of intestinal stromal cells on wound healing and 
their response towards microbiota, their role in immunoregulation 
has also been investigated in IBD. Diminished capacity of IBD 
human colon–derived [myo]fibroblasts to induce FOXP3posCD127neg 
Treg differentiation has been reported. Instead, a FOXP3posCD127pos 
T cell phenotype was generated, which showed a decreased expres-
sion of TGF-β1 and no expression of IL-10 and thereby reduced 
immunosuppressive capacities.53 Another way in which IBD-derived 
stromal cells are able to affect T cells was highlighted by a recent 
study showing that expression of the immune checkpoint PD-L1 
by [myo]fibroblasts is significantly decreased in inflamed CD colon 
compared with that in non-inflamed matched colon samples and co-
lons from healthy controls.95 The decreased PD-L1 expression could 
lead to a decreased suppression of IFN-γ production by Th cells. 
Surprisingly, PD-L1 expression by [myo]fibroblasts in UC tissue was 
increased compared with that in healthy controls, which has been 
linked to an increased capacity to suppress Th1 cell activity in the 
inflamed colon. This observation also suggests a different role for 
Figure 1. Stromal cells in the intestine of IBD patients versus healthy individuals. Different stromal subsets are present in the inflamed bowel. Diminished 
migration capacity in fibroblasts and less stromal cells [green] supporting epithelial cells are found in IBD. Stromal cells directly [via TLRs] and indirectly 
[via microbiota-reactive memory T cells] respond to microbiota by the production of several pro-inflammatory factors. Pathogenic fibroblasts [pink] show 
expression of PDPN, OSMR, mTNF, and FAP, while they produce among others IL-6, IL-13, TNFSF14, and IL-1β. Through for example CCL2 and CXCL12, they 
recruit, respectively, monocytes and T cells towards the inflamed tissue.  Treg – regulatory T cell, PD-L – programmed death-ligand, PDPN – podoplanin, OSMR – 
oncostatin M receptor, FAP – fibroblast activation protein, IFN-y – interferon gamma, CXCL – C-X-C motif chemokine, IL-– interleukin, TNFSF-14 – tumor necrosis 
factor superfamily 14, mTNF – membrane-bound tumor necrosis factor, CCL – chemokine ligand, BMP – bone morphogenetic protein. Some of the figure 
components are derived from the Servier Medical Art library.















































































stromal cells in UC and CD. Unfortunately, in contrast to UC, no 
stromal subset cell analysis has as yet been performed in colonic 
CD, only in ileal CD. In the inflamed colon in UC, the abundance of 
both the S2, already described above, and S4 fibroblast-like popula-
tion was changed.39 While the S4 stroma subset was barely detect-
able in the healthy colon, it was markedly expanded in UC and was 
found to be involved in leukocyte migration, with the expression of 
markers like CCL19, lysyl oxidases, IL-33, and TNFSF14. This was 
confirmed in another recent paper, showing a comparable expanded 
fibroblast population [inflammation-associated fibroblasts] in UC,82 
which showed enrichment for inflammation-associated genes like 
IL-1R1, TNFSF11, and IL-13RA2. Interestingly, the expanded S4 
population,39 activated fibroblasts,83 and inflammation-associated 
fibroblasts were associated with high expression of PDPN, a marker 
which has been identified to be abundantly present in the affected 
tissue of patients with CD or UC,96 as reported in RA.
Stromal cells both produce and respond to cytokines and 
chemokines. The recent scRNA-seq dataset of IBD tissue revealed 
that fibroblasts in the inflamed bowel produce, among other factors, 
monocyte chemoattractant factors [like CCL2, CCL7],83 T cell re-
cruitment factors [like CXCL2, CCL19, CCL21, and CXCL12],39,82 
neutrophil attractants [like CXCL2, CXCL8, and CXCL1],82,83 and 
factors involved in fibrosis [like IL-11, which is also part of the IL-6 
family].82,83,97 Fibroblasts in the inflamed murine colon start producing 
CXCL12 in response to epithelial damage, which will recruit lympho-
cytes towards the mucosa.98 The importance of fibroblast-derived 
CXCL12 on immune cell recruitment has not only been shown in 
intestinal epithelial damage, but also in cancer and RA. In RA, the 
CD34pos subset of stromal cells defined by Mizoguchi and colleagues 
expressed CXCL12 and also other inflammatory genes like CCL2 and 
IL-6.59 The CD90pos subset found in RA by Stephenson and colleagues 
was also characterized by high expression of CXCL12 in comparison 
with the CD90neg subset.57 In contrast, a recent paper from Smillie and 
colleagues showed higher expression of CXCL12 by fibroblasts in the 
healthy colon compared with in UC inflamed colon,82 highlighting the 
need to further explore these findings in follow-up studies.
One of the cytokines that stromal cells can respond to is oncostatin 
M [OSM], by expression of its receptor OSMR or leukemia inhibi-
tory factor receptor [LIFR] and GP130. OSM is produced by hem-
atopoietic cells and was shown to regulate stromal cells in the bone 
marrow by suppressing their differentiation into adipocytes.5,99,100 In 
peripheral tissues, OSM induces a wide range of inflammatory factors 
in stromal cells, like cytokines, chemokines, and leukocyte adhesion 
factors.97 The OSM axis is one of the pathogenic stromal signaling 
pathways in IBD and is implicated in anti-TNF drug resistance.96 
OSM mRNA expression is significantly increased in both CD and 
UC intestinal mucosal biopsies compared with in non-IBD controls, 
and its receptor, OSMR, which is mainly expressed in fibroblasts, is 
also highly expressed in IBD tissue.96 A  close correlation between 
OSM/OSMR expression and histopathological disease severity has 
been reported for IBD.96 In particular, the inflammation-associated 
fibroblasts, which expanded during inflammation in the UC colon, 
showed high OSMR expression.82 Interestingly, cardiac fibroblasts 
showed increased CXCL12 production in response to OSM stimula-
tion101 and could thereby stimulate the recruitment of immune cells 
by fibroblasts. Unpublished data from our group showed high OSM 
levels in CD-associated perianal fistulas, indicating the importance 
of this cytokine in severe complications of IBD as well. In addition to 
OSMR, intestinal fibroblasts also express the IL-17 receptor, which 
upon stimulation has been shown to induce expression of NF-κβ 
inhibitor zeta and CXCL1 in CD colonic fibroblasts, leading to their 
pro-inflammatory phenotype.102 IL-17 was indeed found to be in-
creased in the intestinal mucosa of patients with IBD,103 thereby po-
tentially modifying the activity and chemotaxis of immune cells by 
fibroblasts. The importance of the NF-κβ pathway in stromal cells 
has also been elucidated in a model of colitis-associated cancer, in 
which a specific knockout of IKKβ, an upstream regulator of NF-κβ 
pathway, in COL-VI stromal cells, caused reduced colitis and dys-
plasia development.104 Interestingly, deletion of the same gene in 
COL1α2 stromal cells increased the susceptibility to dysplasia and 
was accompanied by accumulation of Tregs in the tumors.105 This 
clearly shows the differential role of certain pathways in disease 
progression in stromal subsets. Although IL-17 can induce some 
pro-inflammatory pathways in stromal cells,106 it was also sug-
gested that IL-17 is able to downregulate the TNF-α–induced CCL5 
secretion by subepithelial myofibroblasts and thereby immune 
cell recruitment.45 The most well-studied cytokine in IBD is TNF-
α, since it is the main target of the effective and often prescribed 
anti-TNF therapy. Although macrophages are the main TNF-α pro-
ducers, myofibroblasts also signal through transmembrane TNF. 
CD- and UC-derived myofibroblasts from actively inflamed areas 
expressed more transmembrane TNF compared with non-inflamed 
cells or myofibroblasts from healthy controls.107 Thereby CD and 
UC myofibroblasts pose a direct target for anti-TNF-α therapy 
[as discussed in the chapter below]. Furthermore, TNF-α–induced 
genes, like CXCL1, CXCL6, and CCL2, were highly expressed by 
activated fibroblasts found in inflamed CD tissue.83 In addition to 
cytokines, stromal cells also produce the enzyme COX-2, which is 
important for the conversion of arachidonic acid into prostaglandin 
E2. COX-2 expression is, compared with in healthy controls, en-
hanced in the S3 fibroblast subset of UC patients.39 Upregulation of 
COX-2 was also shown before in ileum-derived CD fibroblasts.102 
Specific COX-2 ablation in intestinal myofibroblasts increased sus-
ceptibility to DSS-induced colitis, especially in the initiation phase.108 
These data suggest that COX-2 upregulation by myofibroblasts is 
a regulatory mechanism for controlling inflammation. However, 
for many markers expressed by stromal cells in IBD, their role in 
stimulating or inhibiting ongoing inflammatory responses is as yet 
unknown.
The analysis by Martin and colleagues of inflamed ileal tissue 
from CD patients revealed that the presence of activated fibro-
blasts was highly correlated with the presence of inflammatory 
macrophages, activated dendritic cells, strongly activated T cells, 
IgG-producing plasma cells, and atypical chemokine receptor 1–ac-
tivated endothelial cells.83 They also showed that the inflammatory 
macrophages [CD68posCD206neg] were always in close vicinity of 
PDPNpos fibroblasts. This cell profile associated with high levels 
of activated fibroblasts was only found in a subset of patients and 
did not correlate with, for example, pathologic severity or disease 
duration. The activated fibroblasts strongly expressed CCL2 and 
CCL7, ligands for CCR2, which are expressed by circulating clas-
sical monocytes and facilitates their recruitment in tissues. On the 
other hand, the inflammatory macrophages, likely derived from 
these monocytes, produced inflammatory cytokines like TNF-α, 
IL-1β, OSM, and IL-6, which are all cytokines associated with the 
activation of fibroblasts.83,96
These data show the complexity of versatile, sometimes recip-
rocal, cytokine interactions thereby fine-tuning the function of im-
mune and stromal cells. Taken together, it seems that particular 
subsets of fibroblasts in inflammatory [bowel] diseases can affect the 
immune system both by the production of soluble factors but also 
by direct cell-to-cell contact. The first evidence for subpopulations 















































































of immunoregulatory fibroblasts, identified by for example CD90 
and CD55 expression, and characteristics of pathogenic fibroblasts, 
identified by for example PDPN or CXCL12 expression, are arising.
5. Therapeutic Modalities to Modify the 
Stromal Compartment in IBD
The involvement of stromal cells in the pathogenesis of IBD also 
makes them an interesting therapeutic target. The ultimate goal of 
stromal IBD therapy would be to normalize the stromal cell com-
partment in the inflamed gut, which could be performed in two 
ways [summarized in Figure 2]. The first way is to directly target 
the pathogenic stromal cells that play a role in immune cell recruit-
ment and activation. The identification of these pathogenic stromal 
cell subsets is still ongoing, but several potential subset targets have 
been identified, which we will discuss in more detail below. However, 
because most target molecules will not be organ specific but found 
on stromal cells throughout the whole body, severe side effects 
form a potential risk, and therefore it might be a safer approach to 
normalize the stroma in another way. This could be circumvented 
via the introduction of ‘healthy’ stromal cells, in order to inhibit the 
inflammatory immune response and restore the epithelial cell layer. 
The development of clinical applications using ‘healthy’ allogeneic 
MSCs has been an important field of research in several inflamma-
tory diseases, including IBD, in recent years.
5.1. Targeting stromal cells
Before defining new therapies to target stromal cells, currently ap-
plied IBD medication may also be able to target stromal cells. The 
presence of transmembrane TNF-α on fibroblasts makes them a 
target for anti-TNF-α therapy as well. Anti-TNF-α treatment with 
infliximab on CD-myofibroblasts in vitro increased tissue inhibitors 
of metalloproteinase [TIMP]-1 myofibroblast expression and thereby 
stimulated the migratory potential of the CD myofibroblasts.107 In 
this way, anti-TNF therapy could restore the wound-healing po-
tential of stromal cells in IBD. Next to directly inhibiting TNF-α 
function, anti-TNF-α therapy is able to induce [indirect] apoptosis 
in immune cells.109 Interestingly, CD myofibroblasts revealed to be 
Figure 2. Targeting stromal subsets in luminal IBD- and CD-associated perianal fistulas. 1: Targeting stromal subsets in IBD. Pathogenic stromal cells could be 
directly targeted via surface markers like OSMR, mTNF, PDPN, and FAP, or indirectly by blocking the soluble factors pathogenic stromal cells produce, like LOX. 
2: Local MSC therapy. MSCs modulate immune cell responses, thereby reducing the number of proliferating T cells and stimulating the conversion of T cells into 
regulatory T cells and immunosuppressive ‘M2’ macrophages. Furthermore, they support epithelial regeneration. In these processes, soluble factors like IDO, 
VEGF, HGF, PGE2, and surface markers like PD-L1, ICAM, and MSC-derived exosomes are involved. Treg – regulatory T cell, IL- interleukin, LOX – lysyl oxidase, 
CCL2 – chemokine ligand 2, PDPN – podoplanin, OSMR – oncostatin M receptor, mTNF – membrane-bound tumor necrosis factor, FAP – fibroblast activation 
protein, PGE2 – prostaglandin E2, IDO – indoleamine, PD-L1 – programmed death-ligand 1, TGF-β – transforming growth factor β. Some of the figure components 
are derived from the Servier Medical Art library.















































































resistant to infliximab-induced apoptosis in vitro, which could be ex-
plained by the fact that peripheral blood mononuclear cells [PBMCs] 
are needed for induction of anti-TNF therapy–induced apoptosis in 
fibroblasts.110 In RA, it was found that the TNF-α targeting anti-
bodies infliximab and adalimumab, were less efficient in inducing 
apoptosis in fibroblasts in the presence of PBMCs than etanercept 
via upregulating the anti-apoptotic molecule B cell lymphoma 
[Bcl]-2.110 In IBD patients, the TNFRII-Fc fusion protein etanercept 
[binding only soluble and not transmembrane TNF-α] showed, in 
contrast to the monoclonal antibodies infliximab and adalimumab, 
no clinical efficacy,111 which could suggest that targeting of stromal 
cells by anti-TNF therapy is different in IBD compared with in RA. 
It will be important to unravel to what extent anti-TNF-α therapy 
is affecting stromal cells in IBD patients and to elucidate a poten-
tial subtype of patients that would benefit more from etanercept, 
perhaps in adjunct to infliximab or adalimumab, since it is thought 
to have a higher apoptotic potential for fibroblasts. Interestingly, 
the intestinal cell profile detected in some of the CD patients in as-
sociation with high levels of activated fibroblasts, was enriched in 
non-responders to anti-TNF therapy in a paediatric CD cohort.83,112 
This suggests that a subtype of activated fibroblasts could play a 
role in resistance to anti-TNF therapy. Also, in the inflamed colon 
of UC patients, it was found that the inflammation-associated fibro-
blasts were especially enriched in pre-treatment samples from pa-
tients who did not respond to anti-TNF therapy.82 So, the presence 
of activated fibroblasts in CD, [characterized by CD90, PDPN, and 
increased IL-6, IL-11, and CCL283], inflammation-associated fibro-
blasts in UC, [showing IL-11, IL-25, and IL-13RA2 expression82], 
and OSMR tissue expression96 was associated with resistance to 
anti-TNF therapy. Characterizing fibroblasts in inflamed tissue at 
diagnosis could therefore be helpful in selecting which patient is 
likely to respond to anti-TNF therapy and in which patients other 
therapeutic strategies should be used.
Potentially pathogenic [myo]fibroblasts in the intestine of IBD 
have been shown to express OSMR,82,96,113 PDPN,39,96 and the S4 
subset39 markers in UC: CCL19, LOX, IL-13, and TNFSF14. LOX 
was also found to be overexpressed by CD stenotic myofibroblasts.114 
LOX inhibition restored both MMP3 activity in stenotic 
myofibroblasts and prevented aberrant ECM contraction. In vivo, 
the Lox/Loxl1 inhibitor β-aminopropionitrile [BAPN] resulted in re-
duced disease severity in a mouse model for colitis.39 Interestingly, 
the sequencing data of the pathogenic S4 subpopulation39 and 
inflammation-associated fibroblasts82 showed that FAP is also 
upregulated in UC stroma. FAP is a proline-selective protease, in-
volved in the procession of other proteins and peptides.115 FAP can 
directly enhance proliferation, migration, and invasion of the cells 
by which it is expressed. Interestingly, CAFs with high expression 
of FAP produced more CCL2.116 Thus, targeting FAP could stop 
IBD-associated fibroblast proliferation and reduce the production of 
CCL2 by fibroblasts, and thereby the recruitment of myeloid cells. 
Anti-FAP therapy to target CAFs has already been tested in clinical 
trials for several malignancies and could also be a potential therapy 
to target the S4 fibroblasts/inflammation-associated fibroblasts in 
UC. The feasibility and safety of targeting FAP in the stroma of pa-
tients was demonstrated by Phase I clinical studies, applying mono-
clonal antibodies to advanced FAP-positive cancer patients.117,118 
No major safety concerns were detected in humans, although ab-
lation of FAP-expressing bone marrow stromal cells was observed 
in mice treated with anti-FAP.119,120 In the meantime, many different 
approaches to potentially blocking FAP via low molecular weight 
compounds, immunoliposomes, vaccines, and chimeric antigen 
receptor [CAR] T cells119 have been developed. Also in a mouse 
model for RA, FAP depletion, even when only depleted in the joints, 
showed resolution of the disease.58 Within the FAPpos cell population, 
PDPNposCD90pos cells seemed to contribute the most to the inflam-
mation, since injection of this specific subpopulation in the joints 
resulted in more severe and sustained joint swelling, compared with 
in the PDPNposCD90neg subpopulation. Ex vivo inhibition of FAP in 
CD strictures demonstrated reduced production of type I  collagen 
and TIMP-1,113 which suggest that anti-FAP therapy could be also 
targeting [IBD-related] fibrosis.
Next to FAP and LOX targeting, the correlation between OSMR 
on fibroblast-like cells and disease activity in IBD patients gives rise to 
exploring OSMR targeting. OSMR targeting by a Fc-tagged soluble 
OSMR-gp130 fusion protein was shown to significantly attenuate 
colitis in an IBD mouse model resistant to anti-TNF therapy.96 
Furthermore, adenoviral transfer of OSM also reduced the severity 
of DSS-induced colitis.121 A Phase II clinical trial was performed for 
an anti-OSM humanized monoclonal antibody [GSK315234] in RA. 
The data from this study did not show potent clinical efficacy, but it 
demonstrated the safety of the drug.122 Further exploring the role of 
the OSMR on stromal cells in IBD might optimize patient selection 
for anti-OSM therapy in IBD. In this regard the effectiveness of JAK 
inhibitors in IBD is interesting, since the JAK pathway is downstream 
of the OSMR and therefore the effects of JAK inhibitors on stromal 
cells could teach us more about the OSM–OSMR pathway.123 As de-
scribed before, PDPN is also upregulated in pathogenic IBD stromal 
cells. PDPN regulates cell shape and movement, and is thereby in-
volved in cell migration.124,125 In the meantime, it is also the ligand 
for C-type lectin-like receptor 2, expressed by platelets and some 
subtypes of myeloid cells, and involved in chemokine and cytokine 
production.126 Targeting PDPN could therefore potentially block the 
interaction with myeloid cells. In preclinical studies targeting PDPN, 
using CAR-T cells, antibodies, and lectins, successfully inhibited the 
growth of PDPNpos tumor cells.127 In RA, it was shown that anti-
PDPN antibodies protected mice from collagen-induced arthritis by 
targeting the PDPN-expressing synovial fibroblasts.128 It would be 
interesting to unravel whether this process is mediated by decreased 
fibroblast migration or the interaction with platelets or myeloid 
cells. No studies to target PDPN in mouse models of experimental 
colitis have been reported yet. Interestingly, Th17 cells also express 
PDPN,129 suggesting anti-PDPN is able to target both pathogenic 
stromal and immune cells.
5.2. MSC therapy
MSCs are multipotent stromal cells that are able to differen-
tiate, at least in vitro, into a variety of cell types and are capable 
of immunomodulation and tissue regeneration.130 MSCs can be 
isolated from different tissues, but are mostly derived from adi-
pose tissue and the bone marrow. In fistulizing CD, treatment with 
MSCs has been shown to be safe and effective [Table 1]. Perianal 
fistulas, which are abnormal passageways between the colon and 
skin around the anus, are a serious complication of CD.131 A study 
from our group132 showed that local application of bone marrow–
derived MSCs led to fistula healing in 80% [4/5] of the patients. 
In accordance with these results, a double-blind placebo-controlled, 
multicentre study showed that local treatment with adipose-derived 
MSCs [Cx601/ darvadstrocel] led to significantly improved fistula 
closure in MSC-treated patients compared with placebo-treated pa-
tients after 24  weeks.133 Accordingly, darvadstrocel has now been 
approved as a treatment for refractory CD–associated perianal fis-
tulas in Europe. Importantly, the clinical effects of MSCs seem to 















































































Table 1. Clinical trials in IBD applying local injection of MSCs. Garcia-Olmo et al.,147 Garcia-Olmo et al.,148 Guadalajara et al.,149 Cho et al.,150 Lee et al.,151 Dietz et al.,152 Ciccocioppo et al.,153 
Ciccocioppo et al.,154 De La Portilla et al.,155 Park et al.,156 Garcia-Arranz et al.,157 Panes et al.,133 Panes et al.,158 Molendijk et al.,132 Barnhoorn et al.134
Local MSC administration – fistulising CD
Indication n Placebo- 
controlled
Cell type Dosage Evaluation Efficacy Placebo  
response rates 





4 no adipose  
autologous
3–30 × 106 8 w healing in 6/8; 
partial closure 
in 2/8





49 [24 MSCs] yes adipose  
autologous
20 × 106 + F / second 
dose [40 × 106 + F]  
if incomplete closure  
after 8 w
8 w healing in 17/24 
[11 with single 




12 m [38 m†] 2 SAEs [not 
MSC-related]
Phase IIb 2009 Garcia-Olmo 





10 no adipose  
autologous
10 × 106, 20 × 106 or 
40 × 106 MSCs/ml  
[proportional to  
fistula size – total  
number: 30–400 × 106]
8 w healing in 3/10; 
partial closure 
in 7/10
– 8 m no AEs Phase I 2013 Cho et al.150
perianal CD 
fistulas
43 [completed 33] no adipose  
autologous
30–60 × 106 MSCs/cm 
[proportional to fistula 
size] + F / second dose 
[1.5× more MSCs] if 
incomplete closure  
after 8 w
8 w healing in 27/33, 
incomplete 
closure in  
6/33
– 12 m no AEs Phase II 2013 Lee et al.151
perianal CD 
fistulas
12 no adipose  
autologous
20 × 106 6 m healing in  
10/12




10 no bone 
marrow  
autologous




and 3, 6 and 12 
months later
healing in 7/10, 
incomplete 
closure in  
3/10
– 12 m [60 m‡] no AEs Phase I 2011 Ciccocioppo 
et al.153 ‡  154
perianal CD 
fistulas 
24 [completed 16] no adipose 
allogeneic
20 × 106 / second 
dose [40 × 106] if 
incomplete closure 
after 12 w
12 w and 24 w healing in  
8/16









6 no adipose 
allogeneic
10 × 106 or 30 × 106 
MSCs/ml [proportional 
to fistula size]
8 w healing in 3/6 – 8 m no AEs Phase I 2015 Park et al.156
CD fistulas 
[rectovaginal]
10 [completed 5] no adipose 
allogeneic
20 × 106 / second dose 
[40 × 106] if incomplete 
closure after 12 w





212 [107 MSC] yes adipose 
allogeneic




12 m 5 MSC-related 
SAEs




21 [15 MSC] yes bone 
marrow 
allogeneic
10 × 106, 30 × 106 or 
90 × 106
6 w, 12 w and 
24 w
healing in 9/15 healing in: 2/6 6 m [48 m*] 2 SAEs [not 
MSC-related*]
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Table 2. Clinical trials in IBD applying intravenous injection of MSCs. Duijvestein et al.159 Dhere et al.160 Liang et al.161 Forbes et al.162 Mayer et al.163 Melmed et al.164 Zhang et al.165
Intravenous MSCs administration – luminal IBD
Indication n Placebo- 
controlled
Cell type Dosage Evaluation Efficacy Placebo response 
rates
Follow-up Safety Clinical 
trial
Year Study
CD 9 no bone marrow 
autologous
2× 1–2 × 106 
MSCs/kg, 7 days 
apart
6 w and 14 w no clinical remission, 
but clinical response 
in 3/9; though in 4/9 
disease worsening
– 14 w no AEs Phase I 2010 Duijvestein 
et al.159
CD 12 no bone marrow 
autologous
2 × 106, 5 × 106 or 
10 × 106 MSCs/kg
2 w clinical response 
in 5/11
– 9 w 7 SAEs [2 MSC- 
related]
Phase I 2016 Dhere et 
al.160
CD/UC 7 [4 CD / 3 UC] no bone marrow 
allogeneic [or 
umbilical cord]
1 × 106 MSCs/kg 3 m clinical remission in 
5/7 [CD 2/4; UC 3/3]
– 6–32 m no AEs Phase I 2012 Liang et 
al.161
CD 16 [completed 15] no bone marrow 
allogeneic
4× 2 × 106MSCs/ 
kg once per week
6 w clinical remission in 
8/15 [clinical response 
in 12/15]
– – no AEs related to 
MSCs
Phase II 2014 Forbes et 
al.162
CD 12 no placenta  
allogeneic
2× 2 × 108 or 8 × 
108 once per week
6 m clinical remission in 
3/12 [clinical response 
in 8]
– 24 m no AEs Phase I 2013 Mayer et 
al.163
CD 50 [34 MSCs] yes placenta  
allogeneic
2× 1.5 × 108, 6 × 
108 [or 12 × 108] 
once per week
4 w and 6 w clinical remission in 
4/28 [clinical  
response in 10/28]
clinical remission 
in 0/16 [clinical 
response in 0/16]
24 m 10 MSC-related SAEs Phase 
Ib/ IIa
2015 Melmed et 
al.164




4× 1 × 106 MSCs/ 
kg once per week
12 m no clinical remission, 
but improved clinical 
and endoscopic scores
no clinical  
remission
12 m no SAEs  2018 Zhang et 
al.165
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remain for a longer period of time, as we were recently able to show 
in our 4-year follow-up study.134 The treatment of luminal IBD with 
MSC therapy has also been investigated in pre-clinical models135–137 
and Phase I/II clinical trials [Table  2]. Systemically applied MSCs 
are able to alleviate experimental colitis in mice,135,136 but in humans 
no convincing clinical responses upon systemic administration were 
observed. Therefore, we focused on local MSC therapy for luminal 
IBD. In pre-clinical experiments, local administration of MSCs in 
the inflamed bowel during endoscopy in DSS-induced colitis in mice 
showed attenuation of colitis,138 and mucosal injections of colon 
derived MSCs were more effective in preventing ulcer development 
compared with intravenously injected MSCs in a colonic wound 
model.139 Recently, a phase I  clinical trial started in the Leiden 
University Medical Center [https://www.trialregister.nl/trial/6949; 
EudraCT number: 2017-003524-75] to determine the safety of local 
MSC injections in the bowel of patients with refractory ulcerative 
proctitis.
MSC therapy could be seen as an approach to normalize the in-
testinal stroma by the introduction of healthy allogeneic MSCs. Our 
unpublished data showed, for example, that MSCs express much 
lower levels of the pathogenic fibroblast marker PDPN, compared 
with IBD-derived fibroblasts, which demonstrates their ‘healthy’ 
phenotype. Like fibroblasts, MSCs are able to modulate local in-
flammation as well as to support epithelial regeneration. It has been 
suggested that MSCs are able to suppress immune cell responses 
through secretion of paracrine factors and by cell–cell contacts.90 
Furthermore, it has been postulated that the therapeutic effects of 
MSCs in perianal fistulizing CD is partly due to their PD-L1 expres-
sion.34 When focusing on the effects of MSCs on epithelial repair, 
we showed the ability of MSCs to enhance epithelial proliferation 
and migration via secreted soluble factors, but also to some extent 
via MSC-derived exosomes.140 Next to pro-regenerative and direct 
immune suppressive functions, recently a new hypothesis regarding 
the workings mechanism has been postulated, in which MSCs upon 
intravenous injection undergo apoptosis and effect immunosup-
pression via modulation of the monocytes by which they have been 
phagocytosed.141,142 However, there are no data available yet that 
show that local MSC therapy works in a comparable manner, and 
our published data show at least the engraftment and survival of lo-
cally injected MSCs up to 6 days post-injection.138
While stromal cell therapy is mainly focused on the use of MSCs, 
other stromal cells, like fibroblasts may also be capable of stimu-
lating tissue repair and suppressing immune responses. In a Phase II 
trial, spray-applied allogeneic neonatal keratinocytes and fibroblasts 
successfully treated chronic venous leg ulcers.143 Furthermore, trans-
plantation of autologous skin fibroblasts and adipose tissue,144,145 
including stromal cells, has also been suggested for the treatment of 
CD perianal fistulas.146
6. Conclusion
Although unraveling the role of stromal cells in IBD pathogenesis 
has just started, current research is already showing a considerable 
role for the various subsets of intestinal stromal cells. In this review, 
we focused on their heterogeneity and the role of stromal subtypes 
on epithelial repair and immune homeostasis.
There are several challenges investigating and reporting on 
stromal cells in IBD. One of the difficulties in stromal research 
is the lack of agreement on the exact and uniform definition of 
stromal cell subtypes. Although there seems to be agreement on 
general fibroblast markers, the use of these markers varies between 
studies. This makes it difficult to generate a clear overall picture of 
the recent findings on the various subtypes of stromal cells, as it is 
unclear whether all studies were actually examining the same cell 
type. Furthermore, certain subtype definitions do not withstand 
close scrutiny. For example, the α-SMApos myofibroblast was always 
thought to be important for epithelial homeostasis; however, several 
recent studies also showed that α-SMAneg stromal cells surround the 
epithelial crypt and produce factors important for epithelial homeo-
stasis. Based on the relatively low number of published studies so far, 
it seems there is high heterogeneity between individuals, organs, and 
diseases. In addition, the different isolation and analysis techniques 
used resulted in the identification of different subtypes. Addressing 
these problems and setting a stricter definition of stromal cell types 
would allow a more accurate and representative subclassification.
Many of the studies discussed in this review have analysed cul-
tured stromal cells, which might have changed phenotype and func-
tions compared with their in vivo counterparts. For example, the 
immunomodulatory properties of healthy intestinal stromal cells 
were shown in many studies using cultured fibroblasts. However, 
in freshly isolated cells in viv , only a subpopulation of fibroblasts 
expressed factors that could potentially affect immune cells.39,82 In 
addition, in most studies the effects of medication used by the pa-
tient on the function and expression profile of stromal cells has not 
yet been taken into account. This could have biased results, since for 
example anti-TNF therapy might also directly influence fibroblasts, 
as indicated above.
Although IBD is mentioned as one disease entity, there are 
interesting differences between UC and CD, and also between 
stromal cells in CD and UC, which need to be studied in more detail 
in the future. More generally, it will also be important to unravel 
which changes in stromal cell subsets are ‘inflammation’-mediated 
and which changes are ‘IBD-specific’. Data from other inflamma-
tory disease of the gut, like infectious or microscopic colitis, should 
shed light on this. New technological advances, allowing the analysis 
of non-cultured fibroblasts and the screening of many samples in 
depth, for both RNA and protein expression profiles, are expected 
to extend the knowledge of stromal cells in the inflamed and non-
inflamed gut. However, in addition to the phenotype of stromal cells, 
their function needs to be elucidated further, and therefore more ad-
vanced three-dimensional culture systems and transgenic rodent sys-
tems will be needed to unravel the complex and mutually interactive 
role of human intestinal stromal cells in contact with immune cells 
and epithelial cells.
Direct targeting of pathogenic stromal cells in IBD is still diffi-
cult, since the specific pathogenic subtypes are not yet well defined. 
The challenge lies in restoration of the stromal cells that support 
the epithelial cells, while targeting the stromal cells that attract and 
aberrantly activate immune cells. For now, the introduction of local 
MSCs seems to be a safer option in order to modify the stromal 
component in IBD, since many potential stromal targets would also 
be targeted for healthy stromal cells in other organs. Furthermore, 
since stromal cells seems to be involved in anti-TNF resistance, the 
characterization of stromal cells in inflamed tissue at diagnosis could 
be helpful in predicting disease course and therapeutic responses. In 
conclusion, the field of stromal IBD research is developing and will 
improve knowledge of the pathogenesis of both UC and CD in the 
coming decade, hopefully providing novel insights and therapeutic 
approaches.
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